Last $14.35 USD
Change Today +0.62 / 4.52%
Volume 143.3K
TKAI On Other Exchanges
Symbol
Exchange
NASDAQ GM
Munich
As of 5:20 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

tokai pharmaceuticals inc (TKAI) Snapshot

Open
$13.73
Previous Close
$13.73
Day High
$14.56
Day Low
$13.65
52 Week High
09/17/14 - $30.00
52 Week Low
10/10/14 - $9.67
Market Cap
321.2M
Average Volume 10 Days
79.6K
EPS TTM
--
Shares Outstanding
22.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TOKAI PHARMACEUTICALS INC (TKAI)

Related News

No related news articles were found.

tokai pharmaceuticals inc (TKAI) Related Businessweek News

No Related Businessweek News Found

tokai pharmaceuticals inc (TKAI) Details

Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.

14 Employees
Last Reported Date: 09/18/14
Founded in 2004

tokai pharmaceuticals inc (TKAI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $422.0K
Compensation as of Fiscal Year 2013.

tokai pharmaceuticals inc (TKAI) Key Developments

Tokai Pharmaceuticals Announces Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer

Tokai Pharmaceuticals, Inc. announced updated interim results from its ongoing ARMOR2 Phase 2 clinical trial of galeterone in castration-resistant prostate cancer (CRPC) patients. These interim results from the trial support the potential of galeterone to treat CRPC expressing androgen receptor (AR) splice variants, including AR-V7. The presence of AR C-terminal loss generally, and AR-V7 specifically, has been linked to poor responsiveness to hormonal agents commonly used to treat CRPC. The data were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in an oral presentation titled "Activity of Galeterone in Castrate-Resistant Prostate Cancer (CRPC) with C-Terminal AR Loss: Results from ARMOR2" by Mary-Ellen Taplin, M.D., Associate Professor of Medicine, Director of Genitourinary Clinical Research, Dana-Farber Cancer Institute, Harvard Medical School, and co-principal investigator of ARMOR2. In Part 2 of ARMOR2, the company is characterizing circulating tumor cells for the presence of AR C-terminal loss. As previously reported, seven treatment-naïve CRPC patients have been identified as having C-terminal loss in a retrospective subset analysis; six of these patients had maximal reductions in PSA levels of at least 50%. The seventh patient, who did not show any PSA reduction, discontinued therapy due to an adverse event unrelated to galeterone after approximately six weeks in the trial and did not receive the full 12 week treatment regimen. As of October 14, 2014, the data cutoff for the presentation, the median time to PSA progression among the seven patients is 7.3 months, as defined by the Prostate Cancer Working Group 2 (PCWG2) criteria. Of the six responders with AR C-terminal loss, four elected to continue into an optional extension phase of the trial following the initial 12 week treatment period. As of October 14, 2014, the time on treatment for these patients in the extension phase ranged from 155 days to more than 334 days.

Tokai Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Tokai Pharmaceuticals, Inc. announced consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company announced loss from operations of $6,424,000 compared to $3,365,000 a year ago. Net loss attributable to common stockholders was $6,390,000 or $2.71 per basic and diluted share compared to $3,365,000 or $6.82 per basic and diluted share a year ago. For the nine months, the company announced loss from operations of $17,201,000 compared to $10,200,000 a year ago. Net loss attributable to common stockholders was $171,088,000 or $15.19 per basic and diluted share compared to $10,279,000 or $26.36 per basic and diluted share a year ago.

Tokai Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 08:35 AM

Tokai Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 08:35 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Jodie Pope Morrison, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKAI:US $14.35 USD +0.62

TKAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TKAI.
View Industry Companies
 

Industry Analysis

TKAI

Industry Average

Valuation TKAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TOKAI PHARMACEUTICALS INC, please visit www.tokaipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.